Stockscreener 앱 받기
0.4569
5.33%
-0.0257
시간 외 거래:
.46
0.0031
+0.68%
전일 마감가:
$0.4826
열려 있는:
$0.45
하루 거래량:
8.36M
Relative Volume:
1.52
시가총액:
$106.53M
수익:
$52.29M
순이익/손실:
$-134.84M
주가수익비율:
-0.6092
EPS:
-0.75
순현금흐름:
$-117.11M
1주 성능:
-18.64%
1개월 성능:
-10.60%
6개월 성능:
-60.27%
1년 성능:
-50.12%
1일 변동 폭
$0.42
$0.4643
1주일 범위
$0.42
$0.5788
52주 변동 폭
$0.4111
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
명칭
Sangamo Therapeutics Inc
전화
(510) 970-6000
주소
501 CANAL BLVD., RICHMOND, CA
SGMO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.4569 | 130.04M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 업그레이드 | Truist | Hold → Buy |
| 2024-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-01-07 | 재개 | Guggenheim | Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-12-16 | 재개 | H.C. Wainwright | Buy |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | SunTrust | Buy |
| 2019-08-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2018-10-10 | 개시 | Guggenheim | Buy |
| 2018-06-20 | 개시 | BofA/Merrill | Buy |
| 2017-11-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2016-11-01 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-10-19 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-10-23 | 재개 | Jefferies | Buy |
| 2013-05-03 | 개시 | BioLogic Equity Research | Sell |
| 2011-02-23 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-07-29 | 재확인 | Wedbush | Outperform |
| 2009-10-19 | 개시 | Brean Murray | Sell |
| 2009-10-07 | 재확인 | Leerink Swann | Outperform |
| 2009-08-25 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
Sangamo Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Healthcare Sector Analysts Weigh In on Sangamo Biosciences, Pliant Therapeutics, and Zimmer Biomet Holdings - AInvest
Transcript : Sangamo Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Sangamo: Q2 Earnings Snapshot - Greenwich Time
Earnings call transcript: Sangamo Therapeutics Q2 2025 earnings miss, stock drops - Investing.com Australia
Sangamo Q2 2025 slides: Neurology pipeline advances amid financial challenges - Investing.com Australia
Sangamo Therapeutics Inc (SGMO) Q2 2025 Earnings Call Highlights: Promising Fabry Disease ... By GuruFocus - Investing.com Canada
Sangamo Therapeutics Reports Strong Q2 2025 Results - TipRanks
Sangamo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Sangamo Therapeutics Q2 Misses Revenue Estimates and Reiterates 2025 Guidance — What This Means for Its Strategic Path Forward - AInvest
Sangamo Therapeutics earnings missed by $0.06, revenue fell short of estimates - Investing.com
Sangamo Therapeutics Q2 revenue misses estimates - MarketScreener
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results - Morningstar
Sangamo Therapeutics Announces Second Quarter 2025 Earnings CallLife Science Industry News - Zenopa
Is Sangamo Therapeutics Inc. stock overvalued or undervaluedHigh-yield market plays - Jammu Links News
What are Sangamo Therapeutics Inc. company’s key revenue driversBuild a diversified portfolio for steady growth - Jammu Links News
How does Sangamo Therapeutics Inc. compare to its industry peersGet timely alerts on market opportunities - Jammu Links News
Why is Sangamo Therapeutics Inc. stock attracting strong analyst attentionGet daily updates on top-performing stocks - Jammu Links News
What institutional investors are buying Sangamo Therapeutics Inc. stockRapid growth trajectories - Jammu Links News
Does Sangamo Therapeutics Inc. stock perform well during market downturnsBuild wealth faster with consistent investment plans - Jammu Links News
Is Sangamo Therapeutics Inc. a good long term investmentBuild a portfolio with strong long-term growth - Jammu Links News
What makes Sangamo Therapeutics Inc. stock price move sharplyInvest smarter with daily market updates - Jammu Links News
When is Sangamo Therapeutics Inc. stock expected to show significant growthAccess powerful market insights for free - Jammu Links News
What drives Sangamo Therapeutics Inc. stock priceInvest smarter with expert stock picks - Jammu Links News
What are the technical indicators suggesting about Sangamo Therapeutics Inc.Free Stock Index Interpretation - Jammu Links News
Sangamo Therapeutics Announces Q2 2025 Earnings Call and Webcast - AInvest
How strong is Sangamo Therapeutics Inc. company’s balance sheetDaily Trading Strategy For Smart Trading - Jammu Links News
Has Sangamo Therapeutics Inc. formed a bullish divergenceOversold Bounce Stock Play Ideas Gain Attention - metal.it
Published on: 2025-07-30 16:12:38 - beatles.ru
Will Sangamo Therapeutics Inc. outperform the marketAI Trading Suggestions With Accuracy Focus Released - metal.it
Hunter Syndrome Treatment Market Exclusive Report with - openPR.com
How volatile is Sangamo Therapeutics Inc. stock compared to the marketAI Powered Updates From AI Tools - Jammu Links News
What is the dividend policy of Sangamo Therapeutics Inc. stockDiscover high-impact stocks for growth - Jammu Links News
What are the latest earnings results for Sangamo Therapeutics Inc.Free Stock Updates For 2025 - jammulinksnews.com
Published on: 2025-07-28 06:51:50 - Jammu Links News
Why Sangamo Therapeutics Inc. stock is on top investor watchlistsSafe and Scalable Investment Tips - metal.it
Published on: 2025-07-27 08:45:15 - metal.it
How Sangamo Therapeutics Inc. stock performs during market volatilityChart Breakout Alert - metal.it
Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy - MSN
Sangamo Therapeutics Inc (SGMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):